{
    "2021-11-25": [
        [
            {
                "time": "",
                "original_text": "医药行业2021年三季报总结报告：恢复高成长 医药进入估值切换长周期",
                "features": {
                    "keywords": [
                        "医药行业",
                        "三季报",
                        "恢复高成长",
                        "估值切换",
                        "长周期"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "疫苗概念发力拉升，康泰生物等走强，新冠疫苗出口明年或迎来黄金时期",
                "features": {
                    "keywords": [
                        "疫苗概念",
                        "康泰生物",
                        "新冠疫苗",
                        "出口",
                        "黄金时期"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "华鑫证券：给予康泰生物买入评级",
                "features": {
                    "keywords": [
                        "华鑫证券",
                        "康泰生物",
                        "买入评级"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "华鑫证券维持康泰生物推荐评级：重磅品种放量在即，产品梯队稳步推进",
                "features": {
                    "keywords": [
                        "华鑫证券",
                        "康泰生物",
                        "重磅品种",
                        "放量",
                        "产品梯队",
                        "稳步推进"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}